Albany Molecular Research, Inc. (AMRI) has been awarded a 5 year contract, valued up to $43 million, to help the NIH/NINDS develop at least one Phase I clinical trial candidate. The drug discovery company will provide integrated medicinal chemistry services to its collaborators in the NIH Blueprint Neurotherapeutics Network.
Click here to read more.
Share this:
